Skip to main content

Table 1 Distribution of patients based on thromboelastography determined coagulability (G), cancer type and disease progression group

From: Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression

TEG G

N(ct)

CM

COS

OS

STS

M

L

N(dp)

DM

RM

LI

LNI

Normo

(3.2-7.2)

29.6%

(21)

21.7%

(5)

0%

(0)

33.3%

(2)

46.2%

(6)

41.7%

(5)

30%

(3)

29.1%

(16)

20%

(2)

0%

(0)

29.7%

(11)

100%

(3)

Hyper

(> 7.2)

66.2%

(47)

69.6%

(16)

100%

(7)

66.7%

(4)

53.8%

(7)

58.3%

(7)

60%

(6)

67.3%

(37)

70%

(7)

80%

(4)

70.3%

(26)

0%

(0)

Hypo

(< 3.2)

4.2%

(3)

8.7%

(2)

0%

(0)

0%

(0)

0%

(0)

0%

(0)

10%

(1)

3.6%

(2)

10%

(1)

20%

(1)

0%

(0)

0%

(0)

N

71

23

7

6

13

12

10

55

10

5

37

3

  1. In percentage is the proportion of patients for the given cancer type or disease progression group.
  2. TEG G = Coagulability measured by TEG G; N(ct) = Percentage and number of patients (in total) evaluated by cancer type; CM = Carcinoma located in the mammary gland; COS = Carcinoma located at other sites than the mammary gland; OS = Osteosarcoma; STS = Soft tissue sarcoma; M = Mastocytoma; L = Lymphoma; N(dp) = Percentage and number of patients (in total) evaluated by disease progression group; DM = Distant metastases; RM = Regional metastases; LI = Local invasive; LNI = Local non-invasive.